On August 15, 2013, the FDA put out yet another Safety Announcement concerning fluoroquinolone drugs such as Levaquin, Cipro and Avelox which states that these drugs will now be required to contain a warning for severe, permanent and disabling peripheral neuropathy. The FDA Safety Announcement also indicates that damage can occur in the very beginning of treatment with fluoroquinolone drugs and the damage can be permanent or last for years after treatment is stopped. (See 2017 updated warnings below under Official Safety Announcement from the FDA)
What is peripheral neuropathy? The FDA describes Peripheral neuropathy as follows: Peripheral neuropathy is a nerve disorder occurring in the arms or legs. Symptoms include pain, burning, tingling, numbness, weakness, or a change in sensation to light touch, pain or temperature, or the sense of body position.
Adverse Effect History of Fluoroquinolone Drugs
The quinolones are a family of synthetic broad-spectrum antibacterial drugs. The first generation of quinolones began with the introduction of nalidixic acid in 1962 for treatment of urinary tract infections in humans. Nalidixic acid was discovered by George Lesher and coworkers in a distillate during an attempt at chloroquine synthesis. Quinolones exert their antibacterial effect by preventing bacterial DNA from unwinding and duplicating. The majority of quinolones in clinical use belong to the subset fluoroquinolones, which have a fluorine atom attached to the central ring system, typically at the 6-position or C-7 position.
Ciprofloxacin (CIPRO) is the most widely used of the second-generation quinolone antibiotics that came into clinical use in the late 1980s and early 1990s. In 2010, over 20 million outpatient prescriptions were written for ciprofloxacin, making it the 35th-most commonly prescribed drug, and the 5th-most commonly prescribed antibacterial, in the US. Ciprofloxacin was first patented in 1983 by Bayer A.G. and subsequently approved by the US Food and Drug Administration (FDA) in 1987. Ciprofloxacin has 12 FDA-approved human uses and other veterinary uses, but it is often used for unapproved uses (off-label).
In July of 2008 the FDA issued the following Safety Announcement about fluoroquinolone drugs: FDA is notifying the makers of fluoroquinolone antimicrobial drugs for systemic use of the need to add a boxed warning to the prescribing information about the increased risk of developing tendinitis and tendon rupture in patients taking fluoroquinolones and to develop a Medication Guide for patients.
In 2010, Levaquin was the best-selling antibiotic in the United States. But by 2011 it was also the subject of more than 2,000 lawsuits from patients who had suffered severe reactions after taking it.
As many as one-third of patients taking a fluoroquinolone will experience some sort of negative psychiatric effect, such as anxiety, personality changes, or confusion. The psychiatric effects of the fluoroquinolones are under appreciated by the medical profession as well as by the public. The bigger the gun you use, the more damage you can expect as collateral. David A. Flockhart, professor of medicine and chief of clinical pharmacology at Indiana University School of Medicine.
In a 2001 study by Dr. Jay Cohen, the following reaction rates were documented:(1)
- Nervous system symptoms occurred in 91 percent of patients (pain, tingling and numbness, dizziness, malaise, weakness, headaches, anxiety and panic, loss of memory, psychosis)
- Musculoskeletal symptoms in 73 percent of patients (tendon ruptures, tendonitis, weakness, joint swelling)
- Sensory symptoms in 42 percent of patients (tinnitus, altered visual, olfactory, and auditory function)
- Cardiovascular symptoms in 36 percent of patients (tachycardia, shortness of breath, chest pain, palpitations)
- Skin reactions in 29 percent of patients (rashes, hair loss, sweating, intolerance to heat or cold)
- Gastrointestinal symptoms in 18 percent of patients (nausea, vomiting, diarrhea, abdominal pain)
In a letter to his Congressman, Dr. Cohen wrote the following:
These severe reactions are occurring in patients who are usually healthy, active, and young. Most often, the antibiotics are prescribed for mild infections such as sinusitis, urinary or prostate infections. Most reactions occur very quickly, sometimes with just a few doses of the fluoroquinolone antibiotic. Reactions are acute, severe, frightening, and often disabling. Since the publication of my article with its 45 cases two and a half years ago, I have received e-mails from more than 100 people seeking help for their reactions. In most cases, their doctors have dismissed their complaints or outright denied that the reactions could occur with fluoroquinolones. Yet extensive medical workups do not find any other cause. Worse, there are no known effective treatments. Thus, these people suffer pain and disability for weeks, months, and years.
Another concern is that fluoroquinolones are usually inappropriately prescribed. Instead of being reserved for use against serious, perhaps life-threatening bacterial infections like hospital-acquired pneumonia, these antibiotics have been frequently prescribed for sinusitis, bronchitis, earaches and other illnesses that could resolve on their own or could be treated with less potent drugs or non-drug remedies — or are caused by viruses, which are not susceptible to antibiotics.(2)
See the THE MECHANISMS OF FLUROQUINILONE-ASSOCIATED DISABILITY (Cipro,floxacin, Levaquin, Avelox) PDF CHART for more info. Also check out the “Dear Colleague” letter by Dr. Miriam J. de Jong which provides many, many resource for the chart. It can be read HERE.
- tendon rupture
- peripheral neuropathy
- retinal detachment
- fibromyalgia symptoms
- liver injury
- kidney injury
- dry eyes, mouth and skin
- ringing in ears
- delayed urination
- uncontrollable shaking
- burning pain in eyes and feet
- tingling in hands and feet
- heart palpitations
- muscle spasms
- central nervous system injury (causing “brain fog,” depression, hallucinations and psychotic reactions)
- Hematologic abnormalities such as anemia, methemoglobinemia, leukopenia, granulo-cytopenia, increased or decreased prothrombin time, and increased or decreased platelet counts
- skin (painful, disfiguring rashes and phototoxicity)
- gastrointestinal system (nausea and diarrhea)
- antibiotic-resistant Staphylococcus aureus (known as MRSA) and severe diarrhea caused by Clostridium difficile. One study found that fluoroquinolones were responsible for 55 percent of C. difficile infections at one hospital in Quebec.
Official Safety Announcement from the FDA
UPDATE: AS OF July 26, 2017: The U.S. Food and Drug Administration (FDA) approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). These medicines are associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system that can occur together in the same patient. As a result, we revised the Boxed Warning, FDA’s strongest warning, to address these serious safety issues. We also added a new warning and updated other parts of the drug label, including the patient Medication Guide
[8-15-2013] (http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm) The U.S. Food and Drug Administration (FDA) has required the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones (see Table for a list) may occur soon after these drugs are taken and may be permanent.
The risk of peripheral neuropathy occurs only with fluoroquinolones that are taken by mouth or by injection. Approved fluoroquinolone drugs include levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), and gemifloxacin (Factive). The topical formulations of fluoroquinolones, applied to the ears or eyes, are not known to be associated with this risk.
If a patient develops symptoms of peripheral neuropathy, the fluoroquinolone should be stopped, and the patient should be switched to another, non-fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk. Peripheral neuropathy is a nerve disorder occurring in the arms or legs. Symptoms include pain, burning, tingling, numbness, weakness, or a change in sensation to light touch, pain or temperature, or the sense of body position. It can occur at any time during treatment with fluoroquinolones and can last for months to years after the drug is stopped or be permanent. Patients using fluoroquinolones who develop any symptoms of peripheral neuropathy should tell their health care professionals right away.
FDA will continue to evaluate the safety of drugs in the fluoroquinolone class and will communicate with the public again if additional information becomes available.
Facts about the fluoroquinolone drug class
- Antibacterial drugs approved for the treatment or prevention of certain bacterial infections.
- Approximately 23.1 million unique patients received a dispensed prescription for an oral fluoroquinolone product from outpatient retail pharmacies during 2011. Patients receiving a dispensed prescription for ciprofloxacin, levofloxacin, or moxifloxacin accounted for 70%, 28%, and 9% of the total number of patients, respectively, during 2011. Gemifloxacin, ofloxacin, and norfloxacin each accounted for less than 1% of total patients during 2011.
- Within the hospital setting, there were approximately 3.8 million unique patients billed for an injectable fluoroquinolone product during 2011. Levofloxacin, ciprofloxacin, and moxifloxacin accounted for 63%, 28%, and 13% of total unique patients, respectively, during 2011; hospital billing for ofloxacin was not captured.
List of approved Fluoroquinolone Drug products
|Generic name||Contained in Brand name|
|Musculoskeletal and Peripheral Nervous System||Central Nervous System|
|Numbness or tingling or pricking sensation “pins and needles” in arms or legs||Hallucinations|
|Muscle weakness||Suicidal Thoughts|
|Other Body Systems|
|Worsening of myasthenia gravis|
|Abnormal, rapid or strong heart beat|
If you or a loved one have been harmed from the use of fluoroquinolone drugs contact the FDA at:
References & Research
New York Times: Popular Antibiotics May Carry Serious Side Effects
Rubinstein E. History of quinolones and their side effects. Chemotherapy. 2001;47(S2):3-8.
White AR (BSAC Working Party on the Urgent Need: Regenerating Antibacterial Drug Discovery and Development). Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. 2011;66:1948-53.
Coggins, Mark D. PharmD, CGP, FASCP. Fluoroquinolone Antibiotic Risks. Today’s Geriatric Medicine. Vol. 9 No. 5 P. 6. Accessed June 7, 2018.
U.S. Food and Drug Administration. Risk of fluoroquinolone-associated Myasthenia Gravis Exacerbation February 2011 label changes for fluoroquinolones. March 2011. Retrieved at: https://www.ncbi.nlm.nih.gov/pubmed/21879778
Fisk, MC, Hawkins, B. Johnson & Johnson settles 845 Levaquin lawsuits. Bloomberg Businessweek. Nov 2011. Retrieved from: https://www.bloomberg.com/news/articles/2012-11-01/johnson-johnson-reaches-settlement-in-845-levaquin-cases
Flynn R, Eckel E, Zuckerman D. National Research Center for Women and Families. The facts about medication for colds and the flu. May 2011. Retrieved at: http://www.center4research.org/facts-medication-colds-flu/
FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm. Updated June 7, 2016. Accessed June 7, 2018.
US Food and Drug Administration. FDA drug safety communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf. Published August 15, 2013. Accessed June 7, 2018.